April 30th 2024
The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Addition of Daratumumab to Rd/Vd Heightens MRD Negativity Rates in R/R Myeloma
February 18th 2021High rates of sustained MRD negativity were achieved with daratumumab-containing combinations compared with the standard-of-care combinations, according to an exploratory analysis of 2 ongoing clinical trials.
Read More
Off-the-Shelf NK Immunotherapy Is Safe and Promising in B-Cell NHL With Chemotherapy and Transplant
February 16th 2021Early antitumor activity was seen with cord blood–derived natural killer immunotherapy in combination with high-dose chemotherapy and autologous stem cell transplant in patients with B-cell non-Hodgkin lymphoma, according to early results from a phase 2 trial.
Read More
Can BiTE Molecules Make Off-the-Shelf Immuno-Oncology a Reality?
February 15th 2021In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.
Read More
Ruxolitinib Exceeds Response, Survival, and Symptom Burden End Points in Chronic GVHD
February 12th 2021Results from the phase 3, randomized REACH3 trial further demonstrated the benefit of ruxolitinib over BAT in rates for failure-free survival, symptom improvement, and duration of response.
Read More
Orca-T Achieves Impressive Outcomes in Hematologic Malignancies
February 11th 2021Data presented during the 2021 Transplantation and Cellular Therapy Meeting showed that treatment with Orca-T, achieved a significant reduction in cases of graft-versus-host disease and other impressive outcomes.
Read More
Beti-Cel Shows Good Activity in Transfusion-Dependent Children With Beta-Thalassemia
February 10th 2021Results from 2 phase 3 clinical trials showed that use of the investigational gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients under the age of 18 years with transfusion-dependent beta-thalassemia.
Read More
JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS
February 9th 2021A phase 1 study is the first to demonstrate that JSP191 is safe and effective in older patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.
Read More
Narsoplimab Demonstrates Clinical Activity in High-Risk HSCT-TMA
February 9th 2021In a pivotal phase 2 trial, administration of narsoplimab to patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy led to impressive responses and a favorable survival benefit.
Read More
Stem Cells Achieve Potent Immunity Against SARS-CoV2 and Common Human Coronaviruses In Patients
February 8th 2021Finding presented on patients with hematologic malignancies at the 2021 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR show that patients who had undergone a hematopoietic stem cell transplantation can accumulate effective immunity against SARS-CoV2 infection and non-SARS human coronaviruses.
Read More
Data From the RESPONSE Studies Drive Ruxolitinib Use in Polycythemia Vera
January 27th 2021The way I practice, personally, is that if they are older than 60 years, they are automatically high risk, and I will start hydroxyurea. In PV, being over 60 years and/or prior thrombosis automatically makes the patient high risk, so you should probably be starting a cytoreductive therapy.
Read More
Daratumumab + Lenalidomide + Low-Dose Dexamethasone for Patients With Multiple Myeloma
January 26th 2021Sagar Lonial, MD, FACP, explains the importance of daratumumab/lenalidomide/low-dose dexamethasone (DRd) in several key areas, including progression-free survival versus common standard-of-care regimens in the PEGASUS trial, toxicities, and how active patients fare.
Watch